Pharmacovigilance Aspects of Licensing Agreements

This programme will be of interest to all personnel involved in business development and licensing agreements aspects of pharmacovigilance

8 Oct 2019

GBP 699
EUR 979
USD 1,090

Book now

Course overview

Whilst licensing agreements involving medicines are primarily driven by commercial considerations, the successful handling of pharmacovigilance obligations is a critical, but frequently overlooked, consideration. Negotiating the safety arrangements to ensure regulatory compliance by both partners can be a complex process. This is further compounded by a lack of harmonisation and clarity of the regulations around the world.

This seminar will review the existing global requirements relating to pharmacovigilance in contractual agreements. The emphasis will be on practical advice as to how to remain compliant with the legal obligations, how to satisfy good pharmacovigilance practice and quality management requirements, as well as how to promote harmonious business partnerships.

Key issues to be addressed:

  • Making sense of the licensing agreement jungle
  • How to stay compliant with global pharmacovigilance requirements n Understand what the regulators expect
  • Essentials of licensing agreements – safety and business considerations
  • Understand the legal status and role of pharmacovigilance licensing agreements
  • Discuss audit and compliance aspects of third-party agreements

Who should attend

This programme will be of interest to all personnel involved in business development and licensing agreements, including those working in drug safety and pharmacovigilance, regulatory affairs and drug registration, medical directors, R&D directors and company lawyers.

Programme

Global regulatory framework

  • EU, USA and what ICH says
  • How it impacts partnerships
  • What the regulators expect
    • From the pharmacovigilance system
    • From the MAH
    • From the MAH’s partners

Best pharmacovigilance practices in licensing agreements

  • Types of agreement
  • Safety Data Exchange
  • Who is responsible for what?
  • Joint handling of pharmacovigilance issues

Legal aspects

  • The legal status and role of pharmacovigilance agreements
  • Drafting pharmacovigilance agreements
    • Contract basics, dos and don’ts
    • Terminology, form and content
    • Usingtemplates
  • Contractual liability and indemnities
  • Amendment and termination of pharmacovigilance agreements

Audit and compliance aspects of third-party agreements

  • Regulatory expectations and inspections
  • Which agreements to examine at audit
  • What to look for in safety data exchange agreements at pharmacovigilance audit
  • Which partners to audit and how
  • Measuring partner/other party compliance

Workshop – practical aspects of licensing agreements

Final discussion session and questions

Book now

8 Oct 2019
8 Oct 2019 Rembrandt Hotel, London GBP 699.00
EUR 979.00
USD 1,090.00
+ VAT @ 20.00%
Enrol now

Previous customers include...

  • Actavis Group
  • Alcon Laboratories SA
  • ALEXION Europe SAS
  • Almus Pharmaceuticals Ltd
  • Aurobindo Pharma Ltd
  • Baxter Innovations GmbH
  • Bayer Healthcare
  • Bayer plc
  • Blue Earth Diagnostics
  • Boehringer Ingelheim
  • CILAG AG INTERNATIONAL
  • Ginsana SA
  • GlaxoSmithKline
  • Hospira UK Limited
  • Janssen Cilag Ltd
  • Laboratorios Salvat SA
  • Mercury Pharmaceuticals Ltd
  • Merial SAS
  • MILLENNIUM PHARMACEUTICALS LTD
  • Mylan
  • Napp Pharmaceutical Group Ltd
  • NOVARTIS PHARMA AG
  • Parexel International Ltd
  • PHARMACO50
  • Pharmacosmos A/S
  • Pharmatek Consultancy Services
  • Pliva Hrvatska d.o.o.
  • Procter & Gamble Technical Centres Ltd
  • Redline Pharmacovigilance Ltd
  • Waymade Plc

Christine was a good speaker regarding the legal aspects.

Smitha Bhat, Safety Data Exchange and Quality Scientist , GSK

The course was excellent. I thoroughly enjoyed it. The speakers were clearly very knowledgeable, and were able to answer any questions. The presentations were all very clear and concise, which makes any presentation more enjoyable.

Leah Baker, Pharmacovigilance Scientist, Norgine Ltd

It was good

Sattam Alghodyyr, Pharmacovigilance Manager, SPIMACO

Well structured and insightful

Shirley-Ann Van Der Spuy, EU QPPV, Redline Pharmacovigilance Ltd

Excellent, to the point

Pankaj Nautiyal, ‎Senior Pharmacovigilance Auditor, Glenmark Pharmaceuticals